Mineralys Therapeutics, Inc.

14.23 USD
+0.66 (+4.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Mineralys Therapeutics, Inc. stock is up 12.94% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 1 July’s closed higher than June.

About Mineralys Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. We were originally founded as a Delaware corporation on May 31, 2019 under the name Catalys SC1, Inc. On May 29, 2020, we changed our name to Mineralys Therapeutics, Inc. Our principal executive offices are located at 150 N. Radnor Chester Road, Suite F200, Radnor, PA.